Adagio Medical Holdings, Inc. (NASDAQ:ADGM) shares are up during Monday’s premarket session following the announcement of positive pivotal results for its vCLAS Ventricular Ablation System.



The company on Sunday said the trial demonstrated equivalent effectiveness in treating both ischemic and non-ischemic cardiomyopathy using an endocardial-only approach.



<h2>Adagio Medical Stock Jumps On vCLAS Pivotal Trial Results</h2>



The heart medical device company on Sunday reported six-month results from its FULCRUM-VT Investigational Device Exemption clinical trial, which demonstrated significant safety and effectiveness endpoints.



The results showed an 84% freedom from shock and a 59% freedom from ventricular tachycardia recurrence, which may be driving investor interest as the company seeks FDA approval for its technology, contributing to the stock’s upward movement.



<div>




Read Also:

Also Read: Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges




</div>


The trial included 209 patients and is pivotal for the company’s application for FDA Premarket Approval, marking a key milestone in advancing treatment options for ventricular tachycardia.



The study also demonstrated clinically meaningful de-escalation of the use of amiodarone, an important clinical goal, with a substantial proportion of patients reducing or discontinuing amiodarone therapy post-procedure.



The results also showed a significant reduction in hospital readmission rates compared to those historically reported in the VT ablation literature, underscoring the potential clinical and economic impact of the therapy.



<h2>ADGM Technical Analysis: Momentum And Key Support Levels</h2>



Adagio Medical is currently trading 24.7% above its 20-day simple moving average (SMA) and 46% above its 50-day SMA, indicating strong short-term momentum. The stock also sits 58.9% above its 100-day SMA, suggesting a bullish trend in the intermediate term.



The relative strength index (RSI) is at 60.15, which is neutral, indicating that the stock is not currently overbought or oversold. This level suggests that there is still room for upward movement without immediate pressure from sellers.



<ul>
<li>Key Resistance: $2.50 — This level may act as a barrier for upward momentum.</li>



<li>Key Support: $1.50 — This level could provide a safety net for buyers if tested.</li>
</ul>



Adagio Medical has shown a 12-month return of 21.77%, reflecting a positive longer-term trend. Currently, the stock is trading near its midpoint within the 52-week range, which suggests a stable position as it navigates recent developments.



ADGM Stock Price Activity: Adagio Medical Holdings shares were up 11.92% at $1.69 during premarket trading on Monday, according to Benzinga Pro data.



Image via Shutterstock



<div>



Read Also:

OpenAI Eyes 'AI Agent' Smartphone With Qualcomm And MediaTek, Targets App-Free Experience By 2028: Report



</div>

ADGM

SBIO

Adagio Medical's shares rose 11.92% to $1.69 in premarket trading following positive results from its vCLAS trial, which showed an 84% freedom from shock and a 59% freedom from ventricular tachycardia recurrence. The trial, pivotal for FDA approval, included 209 patients and demonstrated reduced drug use and lower readmission rates. The stock is currently trading significantly above its moving averages, indicating strong momentum, with key resistance at $2.50 and support at $1.50. Adagio has a 12-month return of 21.77%.

Adagio Medical Heart Ablation System Shows 84% Freedom From Shock